Image Source: Unsplash
 

Investors are always looking for stocks that are poised to beat at earnings season and Dick's Sporting Goods, Inc. (DKS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because DICK'S Sporting Goods is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for DKS in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at $3.40 per share for DKS, compared to a broader Zacks Consensus Estimate of $3.34 per share. This suggests that analysts have very recently bumped up their estimates for DKS, giving the stock a Zacks Earnings ESP of +1.80% heading into earnings season.
 

Dick's Sporting Goods, Inc. Price and EPS Surprise

DICK'S Sporting Goods, Inc. price-eps-surprise | DICK'S Sporting Goods, Inc. Quote
 

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns.

Given that DKS has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. 

Clearly, recent earnings estimate revisions suggest that good things are ahead for Dick's Sporting Goods, and that a beat might be in the cards for the upcoming report.

More By This Author:

These Retail Apparel Stocks Are Standing Out In Terms Of Growth & Value This Earnings Season
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates